Moleculin reports 37% blinded remission rate in AML trial interim data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Moleculin reports 37% blinded remission rate in AML trial interim data

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

July 31, 2026 8:10 AM EDT

Prior venetoclax failure a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A

Preliminary blinded CR of 24% and CRc of 37% (n=62), with essentially identical rates among the 30 patients who had failed first-line venetoclax: CR of 23% and CRc of 37% (3X the published salvage remission rates following first-line venetoclax failure of approximately 13%)Enrollment reaches 74 of 90 patients, with final Part A treatment expected in September 2026 and... More